Abstract
Introduction: The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI-3, which began on August 1, 2016, is a 5-year renewal of the current ADNI-2 study. Methods: ADNI-3 will follow current and additional subjects with normal cognition, mild cognitive impairment, and AD using innovative technologies such as tau imaging, magnetic resonance imaging sequences for connectivity analyses, and a highly automated immunoassay platform and mass spectroscopy approach for cerebrospinal fluid biomarker analysis. A Systems Biology/pathway approach will be used to identify genetic factors for subject selection/enrichment. Amyloid positron emission tomography scanning will be standardized using the Centiloid method. The Brain Health Registry will help recruit subjects and monitor subject cognition. Results: Multimodal analyses will provide insight into AD pathophysiology and disease progression. Discussion: ADNI-3 will aim to inform AD treatment trials and facilitate development of AD disease-modifying treatments.
Original language | English (US) |
---|---|
Journal | Alzheimer's and Dementia |
DOIs | |
State | Accepted/In press - 2016 |
Keywords
- Alzheimer's disease
- Amyloid phenotyping
- Brain Health Registry
- Centiloid method
- Clinical trial biomarkers
- Functional connectivity
- Tau imaging
ASJC Scopus subject areas
- Epidemiology
- Health Policy
- Developmental Neuroscience
- Geriatrics and Gerontology
- Clinical Neurology
- Cellular and Molecular Neuroscience
- Psychiatry and Mental health